[Skip to Content]
[Skip to Content Landing]
Viewpoint
October 22/29, 2014

Indication-Specific Pricing for Cancer Drugs

Author Affiliations
  • 1Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York
JAMA. 2014;312(16):1629-1630. doi:10.1001/jama.2014.13235

In 2013, spending on specialty drugs, a category dominated by drugs used to treat cancer, totaled $73 billion.1 That year, 8 new cancer drugs were approved by the US Food and Drug Administration (FDA). The Medicare “price,” which includes patient co-insurance, for these 8 drugs ranged from $7000 to $12 000 per month,2 with some products showing overall survival improvements of nearly 6 months and others showing no improvement in overall survival.

First Page Preview View Large
First page PDF preview
First page PDF preview
×